양극성장애의 인지 장애：미래의 약물치료 타겟 (Cognitive Deficits in Bipolar Disorder：Future Target of Pharmacotherapy)

서지정보

· 발행기관 : 대한우울조울병학회
· 수록지 정보 : Mood and Emotion / 6권 / 2호 / 93 ~ 98페이지
· 저자명 : 유빈, 조현상

초록

In the past, bipolar disorder was understood as an episodic illness involving complete interepisode recovery of the mood and function. But recent studies have focused on the poor functional outcome of bipolar patients, and some researchers think that the poor outcome of bipolar patients may result from the persistent cognitive impairment during symptomatic remission. The cognitive impairment has great importance in patient’s prognosis, because it directly influences their psychosocial functioning. The etiology of cognitive impairment in bipolar patients can be classified into iatrogenic, acute functional changes associated with depression or mania, permanent structural lesions of the neurodegenerative origin or neurodevelopmental origin and permanent functional changes mostly genetic in origin. We
reviewed these causes in this article. Recent treatment strategies are designed to target these causal factors. Generally. the dopaminergic, anticholinergic, and glutamatergic drugs are used in the laboratory fields now. Some studies reported the efficacy of these medications for cognitive improvement in bipolar patients, but these studies were not sufficient to confirm the efficacy of the pharmacotherapy. We also reviewed the rationale and efficacy of the various
psychopharmacotherapies to improve the cognitive function of patients with bipolar disorder. In conclusion, psychopharmacotherapy will be the future plan for the treatment of cognitive impairment of bipolar patients.

영어초록

In the past, bipolar disorder was understood as an episodic illness involving complete interepisode recovery of the mood and function. But recent studies have focused on the poor functional outcome of bipolar patients, and some researchers think that the poor outcome of bipolar patients may result from the persistent cognitive impairment during symptomatic remission. The cognitive impairment has great importance in patient’s prognosis, because it directly influences their psychosocial functioning. The etiology of cognitive impairment in bipolar patients can be classified into iatrogenic, acute functional changes associated with depression or mania, permanent structural lesions of the neurodegenerative origin or neurodevelopmental origin and permanent functional changes mostly genetic in origin. We
reviewed these causes in this article. Recent treatment strategies are designed to target these causal factors. Generally. the dopaminergic, anticholinergic, and glutamatergic drugs are used in the laboratory fields now. Some studies reported the efficacy of these medications for cognitive improvement in bipolar patients, but these studies were not sufficient to confirm the efficacy of the pharmacotherapy. We also reviewed the rationale and efficacy of the various
psychopharmacotherapies to improve the cognitive function of patients with bipolar disorder. In conclusion, psychopharmacotherapy will be the future plan for the treatment of cognitive impairment of bipolar patients.

참고자료

· 없음